3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
trastuzumab deruxtecan
2
Cisplatin
2
Biopsy
2
pembrolizumab
1
luprolide acetate gel depot
1
entrectinib
1
dehydroftorafur
1
darolutamide
1
ceralasertib
1
apalutamide
1
amivantamab
1
Surveys and Questionnaires
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Platinum
1
Pemetrexed
1
Leuprolide
1
Immunoglobulin G
1
Gonadotropin-Releasing Hormone
1
Glutamate Carboxypeptidase II
1
Fluorouracil
1
Docetaxel
1
Disulfides
1
Carboplatin
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.